Nanordica Medical raises €1.6M for antibiotic-free wound treatment
Nanordica Medical’s €1.6 million raise highlights a healthtech approach to chronic wound care that aims to reduce reliance on antibiotics.
Chronic wound care is a major healthcare burden, and antibiotic resistance makes the problem even harder. Nanordica Medical’s raise points to a treatment approach focused on healing without leaning on antibiotics.
What happened
Nanordica Medical raised €1.6 million to bring its antibiotic-free chronic wound treatment closer to market. The company is developing Premotiv, a wound-care technology designed to prevent infection and support healing.
Why it matters
Chronic wounds, including diabetic foot ulcers, can be painful, expensive and difficult to treat. Technologies that reduce infection risk without relying on antibiotics could help patients while also supporting wider efforts against antimicrobial resistance.
The bigger picture
Healthtech is not only about digital platforms and AI. Some of the most important innovation sits in clinical products that address stubborn, everyday healthcare problems with better materials, diagnostics or treatment design.